Eli Lilly and Company (NYSE:LLY) Shares Sold by Davidson Capital Management Inc.

Davidson Capital Management Inc. trimmed its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 8.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,925 shares of the company's stock after selling 372 shares during the period. Eli Lilly and Company accounts for about 0.9% of Davidson Capital Management Inc.'s holdings, making the stock its 16th biggest holding. Davidson Capital Management Inc.'s holdings in Eli Lilly and Company were worth $3,242,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in LLY. FPC Investment Advisory Inc. grew its stake in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares during the period. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $43,000. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $48,000. Highline Wealth Partners LLC raised its holdings in Eli Lilly and Company by 53.3% in the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after buying an additional 24 shares during the period. Finally, Capital A Wealth Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $63,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $6.96 during midday trading on Thursday, reaching $784.28. 2,441,727 shares of the company were exchanged, compared to its average volume of 3,656,357. The stock has a market cap of $743.29 billion, a P/E ratio of 63.81, a PEG ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a fifty day simple moving average of $778.55 and a 200 day simple moving average of $801.58. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.58 earnings per share. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were paid a $1.50 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.